Latest:
Dr Khalil on the Future Investigations of Immunotherapy in NSCLC
Maya Khalil, MD, discusses the future investigations of immunotherapy in non–small cell lung cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Georges Azzi, MD
Latest:
Dr. Azzi on the Utilization of the Signatera ctDNA Assay in the CIRCULATE-US Trial in CRC
Georges Azzi, MD, co-director, Department of Hematology/Oncology, Prostate Cancer, Holy Cross Health, discusses the utilization of the Signatera circulating tumor DNA assay in the ongoing phase 2/3 CIRCULATE-US trial in colorectal cancer.
June-Wha Rhee, MD
Latest:
Dr. Rhee on the Benefit of Zanubrutinib Vs Ibrutinib in R/R CLL
June-Wha Rhee, MD, discusses the benefit of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia, as well as the incidence of cardiac disorders associated with the BTK inhibitors.
Kai-Keen Shiu, MD
Latest:
Dr Shiu on the FDA Approval of Pembrolizumab Plus Chemotherapy in Advanced HER2– Gastric/GEJ Adenocarcinoma
Kai-Keen Shiu, MD, discusses the significance of the FDA approval of pembrolizumab in combination with fluoropyrimidine- and platinum-containing chemotherapy as a first-line treatment in patients with locally advanced, unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Chad Tang, MD
Chad Tang, MD, is an associate professor in the Department of Radiation Oncology of the Division of Radiation Oncology; in the Department of Translational Molecular Pathology; and in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center in Houston.
Latest:
Dr Tang on the Implementation of Metastasis-Directed Radiotherapy in Oligometastatic ccRCC
Chad Tang, MD, discusses potential roadblocks for the clinical use of metastasis-directed radiotherapy for patients with oligometastatic ccRCC.
Chan Cheah, MBBS
Latest:
Updated Results From the Phase 1 Study of Sonrotoclax (BGB-11417), a Novel BCL2 Inhibitor, in Combination With Zanubrutinib for Relapsed/Refractory CLL/SLL, Demonstrate Deep and Durable Responses
Chan Y. Cheah, MBBS, DMSc, shares insights on updated results from the phase 1 BGB-11417 trial that were presented at the 2025 EHA Congress in Milan, Italy. The longer follow-up data demonstrate the safety and efficacy of the sonrotoclax plus zanubrutinib combination in patients with relapsed or refractory chronic lympocytic leukemia and small lymphocytic lymphoma.
Zosia Piotrowska, MD, MHS
Latest:
The Future of Tumor Agnostic Therapies in EGFRm m NSCLC
Experts discuss the expanding treatment landscape for EGFR-mutated non–small cell lung cancer (NSCLC), highlighting emerging strategies beyond tyrosine kinase inhibitors (TKIs)—including novel immunotherapy combinations and antibody-drug conjugates (ADCs)—with particular interest in bispecific antibodies and TROP2-directed ADCs that may offer new options for patients progressing on targeted therapy, despite ongoing challenges in translating immune-based approaches into consistent survival gains.
Coral O. Omene, MD, PhD
Latest:
Dr Omene on the Importance of Access to Breast Cancer Screenings in Underserved Populations
Coral O. Omene, MD, PhD, discusses the need to improve early access to breast cancer screenings for patients in underserved populations and recent updates to the National Comprehensive Cancer Network Guidelines on breast cancer screening.